A Phase 2 interventional study of Lumacaftor and Ivacaftor in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 56 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-10-05.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing lumacaftor in Cystic Fibrosis — none open to participants now, none under way, none of them phase 3. lumacaftor · Cystic Fibrosis.
Among the 20 studies testing lumacaftor in Cystic Fibrosis, this one is the 4th largest by enrollment, is one of 2 that started in 2010, is one of 4 in phase 2, and was the 4th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →None of the 20 studies testing lumacaftor in Cystic Fibrosis is open now. The open studies under Cystic Fibrosis, anywhere →
lumacaftor: first FDA approval 2015 (ORKAMBI), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2010.
This study's enrollment of 312 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 66 across the 20 interventional studies. Of the 20 that completed or were terminated, 15 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 20 have an industry lead sponsor. The 1 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 14th largest by enrollment of the 116 interventional ones that give a count, is one of 7 that started in 2010, is one of 21 in phase 2, and was the 14th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing lumacaftor in Cystic Fibrosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate of the safety, efficacy, pharmacokinetics (PK) and pharmacodynamic (PD) effects of lumacaftor (VX-809) alone and when coadministered with ivacaftor (VX-770) in participants with cystic fibrosis, homozygous or heterozygous for the F508del-CFTR mutation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants homozygous (HO) for the F508del-CF transmembrane conductance regulator gene (CFTR) mutation received lumacaftor matched placebo once daily (qd) (Day 1 through Day 14), followed by lumacaftor matched placebo qd in combination with ivacaftor matched placebo every 12 hours (q12h) (Day 15 through Day 21).
Drug: Lumacaftor Placebo · Drug: Ivacaftor Placebo
Participants homozygous for the F508del-CFTR mutation received 200 milligram (mg) of lumacaftor (LUM) qd (Day 1 through Day 14), followed by 200 mg of lumacaftor qd in combination with 150 mg of ivacaftor (IVA) q12h (Day 15 through Day 21).
Drug: Lumacaftor · Drug: Ivacaftor
Participants homozygous for the F508del-CFTR mutation received 200 mg of lumacaftor alone qd (Day 1 through Day 14), followed by 200 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 15 through Day 21).
Drug: Lumacaftor · Drug: Ivacaftor
Participants homozygous or heterozygous for the F508del-CFTR mutation received lumacaftor matched placebo qd (Day 1 through Day 28), followed by lumacaftor matched placebo in combination with ivacaftor matched placebo q12h (Day 29 through Day 56).
Drug: Lumacaftor Placebo · Drug: Ivacaftor Placebo
Participants homozygous for the F508del-CFTR mutation received 200 mg of lumacaftor alone qd (Day 1 through Day 28), followed by 200 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).
Drug: Lumacaftor · Drug: Ivacaftor
Participants homozygous for the F508del-CFTR mutation received 400 mg of lumacaftor alone qd (Day 1 through Day 28), followed by 400 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).
Drug: Lumacaftor · Drug: Ivacaftor
Participants homozygous or heterozygous for the F508del-CFTR mutation received 600 mg of lumacaftor alone qd (Day 1 through Day 28), followed by 600 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).
Drug: Lumacaftor · Drug: Ivacaftor
Participants homozygous for the F508del-CFTR mutation received 400 mg of lumacaftor alone q12h (Day 1 through Day 28), followed by 400 mg of lumacaftor q12h in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).
Drug: Lumacaftor · Drug: Ivacaftor
Participants heterozygous for the F508del-CFTR mutation received lumacaftor matched placebo in combination with ivacaftor matched placebo q12h (Day 1 through Day 56).
Drug: Lumacaftor Placebo · Drug: Ivacaftor Placebo
Participants heterozygous for the F508del-CFTR mutation received 400 mg of lumacaftor q12h in combination with 250 mg of ivacaftor q12h (Day 1 through Day 56).
Drug: Lumacaftor · Drug: Ivacaftor
Tablet
Also known as: VX-809, LUM
Tablet.
Also known as: VX-770, IVA
Matching placebo tablet.
Matching placebo tablet.
Cohort 1: Safety and Tolerability Based on Adverse Events (AEs)
AE: any untoward medical occurrence in a participant during study; irrespective of relationship with treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after informed consent. AE includes serious AEs (SAEs) as well as Non-SAEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Number of participants with AEs and SAEs are reported. AE that started at/after initial dosing of study drug, or increased in severity after initial dosing of study drug is considered treatment-emergent. Results are reported separately for monotherapy period (Period 1: Day 1 to Day 14) and combination therapy period (Period 2: Day 15 to Day 21).
Time frame: Cohort 1: Day 1 up to 28 days after last dose (Last dose = Day 21)
Cohort 2 and 3: Safety and Tolerability Based on Adverse Events (AEs)
Detailed description is provided in Outcome Measure 1. Results are reported separately for monotherapy period (Period 1: Day 1 to Day 28) and combination therapy period (Period 2: Day 29 to Day 56).
Time frame: Cohort 2 and 3: Day 1 up to 28 days after last dose (Last dose = Day 56)
Cohort 4: Safety and Tolerability Assessed by Number of Participants With AEs and SAEs
AEs and SAEs are defined in Outcome Measure 1.
Time frame: Cohort 4: Day 1 up to 28 days after last dose (Last dose = Day 56)
Cohort 1: Absolute Change From Day 14 in Sweat Chloride at Day 21
Time frame: Cohort 1: Day 14, Day 21
Cohort 2 And 3: Absolute Change From Day 28 in Sweat Chloride at Day 56
Time frame: Cohort 2 and 3: Day 28, Day 56
Cohort 4: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 56
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. ppFEV1 (predicted for age, gender, and height) was calculated using the Hankinson method.
Time frame: Cohort 4: Baseline, Day 56
Cohort 1: Absolute Change From Baseline in Sweat Chloride at Day 14
Time frame: Cohort 1: Baseline, Day 14
Cohort 2 And 3: Absolute Change From Baseline in Sweat Chloride at Day 14
Time frame: Cohort 2: Baseline, Day 14
Cohort 4: Absolute Change From Baseline in Sweat Chloride at Day 56
Time frame: Cohort 4: Baseline, Day 56
Cohort 1: Absolute Change From Day 14 in FEV1 at Day 21
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: Cohort 1: Day 14, Day 21
Cohort 1: Absolute Change From Day 14 in ppFEV1 at Day 21
FEV1 and ppFEV1 are defined in Outcome Measure 6.
Time frame: Cohort 1: Day 14, Day 21
Cohort 2 and 3: Absolute Change From Day 28 in ppFEV1 at Day 56
FEV1 and ppFEV1 are defined in Outcome Measure 6.
Time frame: Cohort 2 and 3: Day 28, Day 56
Cohort 2 and 3: Relative Change From Day 28 in ppFEV1 at Day 56
FEV1 and ppFEV1 are defined in Outcome Measure 6.
Time frame: Cohort 2 and 3: Day 28, Day 56
Cohort 2 and 3: Absolute Change From Baseline in ppFEV1 at Day 28 and 56
FEV1 and ppFEV1 are defined in Outcome Measure 6.
Time frame: Cohort 2 and 3: Baseline, Day 28 and 56
Cohort 2 and 3: Relative Change From Baseline in FEV1 at Day 28 and 56
FEV1 and ppFEV1 are defined in Outcome Measure 6.
Time frame: Cohort 2 and 3: Baseline, Day 28 and 56
Cohort 4: Relative Change From Baseline in Percent Predicted FEV1 at Day 56
FEV1 and ppFEV1 are defined in Outcome Measure 6.
Time frame: Cohort 4: Baseline, Day 56
Cohort 2 and 3: Absolute Change From Day 28 in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Day 56
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for subjects with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
Time frame: Cohort 2 and 3: Day 28, Day 56
Cohort 4: Absolute Change From Baseline in CFQ-R Respiratory Domain Score at Day 56
CFQ-R respiratory domain is defined in Outcome Measure 17.
Time frame: Cohort 4: Baseline, Day 56
Cohort 4: Absolute Change From Baseline in Body Mass Index (BMI) at Day 56
BMI was defined as weight in kilogram (kg) divided by height\*height in square meter (m\^2).
Time frame: Cohort 4: Baseline, Day 56
Cohort 4: Absolute Change From Baseline in Weight at Day 56
Time frame: Cohort 4: Baseline, Day 56
Participants in each cohort are mutually exclusive. A total of 312 participants were randomized of which one participant did not receive any treatment and a total of 311 participants were treated.
| Milestone | Cohort 1: Placebo | Cohort 1: LUM 200 mg qd/LUM 200 mg qd+IVA 150 mg q12h | Cohort 1: LUM 200 mg qd/LUM 200 mg qd+IVA 250 mg q12h | Cohort 2 and 3: Placebo (HO and HE) | Cohort 2: LUM 200 mg qd/LUM 200 mg qd+IVA 250 mg q12h (HO) | Cohort 2: LUM 400 mg qd/LUM 400 mg qd+IVA 250 mg q12h (HO) | Cohort 2: LUM 600 mg qd/LUM 600 mg qd+IVA 250 mg q12h (HO&HE) | Cohort 3: LUM 400 mg q12h/LUM 400 mg q12h+IVA 250 mg q12h (HO) | Cohort 4: Placebo | Cohort 4: LUM 400 mg q12h+IVA 250 mg q12h |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 21 | 20 | 21 | 27 | 23 | 21 | 42 | 11 | 63 | 62 |
| Completed | 21 | 20 | 20 | 27 | 23 | 21 | 41 | 11 | 62 | 57 |
| Not completed | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 5 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 3 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
AE: any untoward medical occurrence in a participant during study; irrespective of relationship with treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after informed consent. AE includes serious AEs (SAEs) as well as Non-SAEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Number of participants with AEs and SAEs are reported. AE that started at/after initial dosing of study drug, or increased in severity after initial dosing of study drug is considered treatment-emergent. Results are reported separately for monotherapy period (Period 1: Day 1 to Day 14) and combination therapy period (Period 2: Day 15 to Day 21).
| participants | Cohort 1: Placebo - Period 1 | Cohort 1: LUM 200 mg qd - Period 1 | Cohort 1: Placebo - Period 2 | Cohort 1: LUM 200 mg qd+IVA 150 mg q12h - Period 2 | Cohort 1: LUM 200 mg qd+IVA 250 mg q12h - Period 2 |
|---|---|---|---|---|---|
| Participants with any AEs | 12 | 29 | 15 | 14 | 12 |
| Participants with SAEs | 0 | 0 | 0 | 0 | 0 |
Detailed description is provided in Outcome Measure 1. Results are reported separately for monotherapy period (Period 1: Day 1 to Day 28) and combination therapy period (Period 2: Day 29 to Day 56).
| participants | Cohort 2 and 3: Placebo (HO and HE) - Period 1 | Cohort 2: LUM 200 mg qd - Period 1 | Cohort 2: LUM 400 mg qd - Period 1 | Cohort 2: LUM 600 mg qd - Period 1 | Cohort 3: LUM 400 mg q12h - Period 1 | Cohort 2 and 3: Placebo (HO and HE) - Period 2 | Cohort 2: LUM 200 mg qd+IVA 250 mg q12h (HO) - Period 2 | Cohort 2: LUM 400 mg qd+IVA 250 mg q12h (HO) - Period 2 | Cohort 2: LUM 600 mg qd+IVA 250 mg q12h (HO&HE) - Period 2 | Cohort 3: LUM 400 mg q12h+IVA 250 mg q12h (HO) - Period 2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Participants with any AEs | 23 | 18 | 18 | 37 | 7 | 20 | 12 | 15 | 26 | 10 |
| Participants with SAEs | 1 | 2 | 0 | 3 | 2 | 4 | 0 | 1 | 4 | 1 |
AEs and SAEs are defined in Outcome Measure 1.
| participants | Cohort 4: Placebo | Cohort 4: Active Study Drug |
|---|---|---|
| Participants with any AEs | 53 | 52 |
| Participants with SAEs | 5 | 9 |
| millimole per liter (mmol/L) | Cohort 1: LUM 200 mg qd+IVA 150 mg q12h - Period 2 | Cohort 1: LUM 200 mg qd+IVA 250 mg q12h - Period 2 | Cohort 1: Placebo - Period 2 |
|---|---|---|---|
| Cohort 1: Absolute Change From Day 14 in Sweat Chloride at Day 21 | -2.131 (-5.381 to 1.119) | -9.128 (-12.893 to -5.362) | 0.548 (-2.955 to 4.052) |
| mmol/L | Cohort 2: LUM 200 mg qd+IVA 250 mg q12h (HO) - Period 2 | Cohort 2: LUM 400 mg qd+IVA 250 mg q12h (HO) - Period 2 | Cohort 2: LUM 600 mg qd+IVA 250 mg q12h (HO) - Period 2 | Cohort 2: LUM 600 mg qd+IVA 250 mg q12h (HE) - Period 2 | Cohort 3: LUM 400 mg q12h+IVA 250 mg q12h (HO) - Period 2 | Cohort 2 and 3: Placebo (HO and HE) - Period 2 |
|---|---|---|---|---|---|---|
| Cohort 2 And 3: Absolute Change From Day 28 in Sweat Chloride at Day 56 | 0.321 (-4.208 to 4.849) | -1.043 (-5.800 to 3.714) | -2.900 (-7.542 to 1.743) | -1.240 (-6.287 to 3.807) | -2.154 (-9.177 to 4.870) | 1.627 (-2.661 to 5.915) |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. ppFEV1 (predicted for age, gender, and height) was calculated using the Hankinson method.
| percent predicted of FEV1 | Cohort 4: Placebo | Cohort 4: LUM 400 mg q12h+IVA 250 mg q12h |
|---|---|---|
| Cohort 4: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 56 | -1.23 ± 0.801 | -0.62 ± 0.829 |
| mmol/L | Cohort 1: LUM 200 mg qd - Period 1 | Cohort 1: Placebo - Period 1 |
|---|---|---|
| Cohort 1: Absolute Change From Baseline in Sweat Chloride at Day 14 | -4.442 (-7.141 to -1.742) | -1.668 (-5.606 to 2.271) |
| mmol/L | Cohort 2: LUM 200 mg qd - Period 1 | Cohort 2: LUM 400 mg qd - Period 1 | Cohort 2: LUM 600 mg qd (HO) - Period 1 | Cohort 2: LUM 600 mg qd (HE) - Period 1 | Cohort 3: LUM 400 mg q12h - Period 1 | Cohort 2 and 3: Placebo (HO and HE) - Period 1 |
|---|---|---|---|---|---|---|
| Cohort 2 And 3: Absolute Change From Baseline in Sweat Chloride at Day 14 | -6.490 (-11.226 to -1.755) | -5.901 (-10.910 to -0.892) | -9.442 (-13.953 to -4.931) | -3.137 (-8.167 to 1.893) | -9.179 (-15.470 to -2.888) | 0.048 (-4.162 to 4.258) |
| mmol/L | Cohort 4: Placebo | Cohort 4: LUM 400 mg q12h+IVA 250 mg q12h |
|---|---|---|
| Cohort 4: Absolute Change From Baseline in Sweat Chloride at Day 56 | -0.78 ± 1.230 | -11.82 ± 1.281 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| liters | Cohort 1: LUM 200 mg qd+IVA 150 mg q12h - Period 2 | Cohort 1: LUM 200 mg qd+IVA 250 mg q12h - Period 2 | Cohort 1: Placebo - Period 2 |
|---|---|---|---|
| Cohort 1: Absolute Change From Day 14 in FEV1 at Day 21 | 0.128 (0.030 to 0.225) | 0.015 (-0.094 to 0.124) | -0.046 (-0.138 to 0.047) |
FEV1 and ppFEV1 are defined in Outcome Measure 6.
| percent predicted of FEV1 | Cohort 1: LUM 200 mg qd+IVA 150 mg q12h - Period 2 | Cohort 1: LUM 200 mg qd+IVA 250 mg q12h - Period 2 | Cohort 1: Placebo - Period 2 |
|---|---|---|---|
| Cohort 1: Absolute Change From Day 14 in ppFEV1 at Day 21 | 3.46 (0.87 to 6.05) | 0.63 (-2.20 to 3.46) | -1.44 (-3.89 to 1.01) |
FEV1 and ppFEV1 are defined in Outcome Measure 6.
| percent predicted of FEV1 | Cohort 2: LUM 200 mg qd+IVA 250 mg q12h (HO) - Period 2 | Cohort 2: LUM 400 mg qd+IVA 250 mg q12h (HO) - Period 2 | Cohort 2: LUM 600 mg qd+IVA 250 mg q12h (HO) - Period 2 | Cohort 2: LUM 600 mg qd+IVA 250 mg q12h (HE) - Period 2 | Cohort 3: LUM 400 mg q12h+IVA 250 mg q12h (HO) - Period 2 | Cohort 2 and 3: Placebo (HO and HE) - Period 2 |
|---|---|---|---|---|---|---|
| Cohort 2 and 3: Absolute Change From Day 28 in ppFEV1 at Day 56 | 1.96 (-0.84 to 4.76) | 1.99 (-0.87 to 4.84) | 6.15 (3.27 to 9.02) | 2.29 (-0.82 to 5.39) | 6.09 (2.02 to 10.16) | -1.57 (-4.24 to 1.09) |
FEV1 and ppFEV1 are defined in Outcome Measure 6.
| percent change | Cohort 2: LUM 200 mg qd+IVA 250 mg q12h (HO) - Period 2 | Cohort 2: LUM 400 mg qd+IVA 250 mg q12h (HO) - Period 2 | Cohort 2: LUM 600 mg qd+IVA 250 mg q12h (HO) - Period 2 | Cohort 2: LUM 600 mg qd+IVA 250 mg q12h (HE) - Period 2 | Cohort 3: LUM 400 mg q12h+IVA 250 mg q12h (HO) - Period 2 | Cohort 2 and 3: Placebo (HO and HE) - Period 2 |
|---|---|---|---|---|---|---|
| Cohort 2 and 3: Relative Change From Day 28 in ppFEV1 at Day 56 | 3.13 (-1.29 to 7.54) | 2.98 (-1.52 to 7.48) | 9.70 (5.17 to 14.23) | 4.30 (-0.59 to 9.19) | 8.24 (1.83 to 14.65) | -2.05 (-6.25 to 2.15) |
FEV1 and ppFEV1 are defined in Outcome Measure 6.
| percent predicted of FEV1 | Cohort 2: LUM 200 mg qd/LUM 200 mg qd+IVA 250 mg q12h (HO) | Cohort 2: LUM 400 mg qd/LUM 400 mg qd+IVA 250 mg q12h (HO) | Cohort 2: LUM 600 mg qd/LUM 600 mg qd+IVA 250 mg q12h (HO) | Cohort 2: LUM 600 mg qd/LUM 600 mg qd+IVA 250 mg q12h (HE) | Cohort 3: LUM 400 mg q12h/LUM 400 mg q12h+IVA 250 mg q12h (HO) | Cohort 2 and 3: Placebo (HO and HE) |
|---|---|---|---|---|---|---|
| Day 28: (n= 21, 20, 20, 18, 11, 27) | 0.21 (-2.77 to 3.19) | -1.35 (-4.39 to 1.69) | -2.62 (-5.67 to 0.42) | -3.82 (-7.03 to -0.61) | -4.52 (-8.65 to -0.39) | -0.03 (-2.68 to 2.62) |
| Day 56: (n= 21, 20, 20, 17, 10, 24) | 1.82 (-1.28 to 4.91) | 0.64 (-2.52 to 3.80) | 3.59 (0.41 to 6.77) | -1.68 (-5.12 to 1.75) | 2.16 (-2.34 to 6.66) | -2.02 (-4.97 to 0.93) |
FEV1 and ppFEV1 are defined in Outcome Measure 6.
| percent change | Cohort 2: LUM 200 mg qd/LUM 200 mg qd+IVA 250 mg q12h (HO) | Cohort 2: LUM 400 mg qd/LUM 400 mg qd+IVA 250 mg q12h (HO) | Cohort 2: LUM 600 mg qd/LUM 600 mg qd+IVA 250 mg q12h (HO) | Cohort 2: LUM 600 mg qd/LUM 600 mg qd+IVA 250 mg q12h (HE) | Cohort 3: LUM 400 mg q12h/LUM 400 mg q12h+IVA 250 mg q12h (HO) | Cohort 2 and 3: Placebo (HO and HE) |
|---|---|---|---|---|---|---|
| Day 28: (n= 21, 20, 20, 18, 11, 27) | 0.24 (-4.27 to 4.75) | -1.15 (-5.75 to 3.45) | -3.13 (-7.74 to 1.48) | -5.46 (-10.32 to -0.60) | -6.39 (-12.65 to -0.14) | 1.89 (-2.12 to 5.90) |
| Day 56: (n= 21, 20, 20, 17, 10, 24) | 2.51 (-2.21 to 7.23) | 1.72 (-3.09 to 6.53) | 5.55 (0.70 to 10.39) | -2.34 (-7.57 to 2.89) | 2.96 (-3.90 to 9.81) | -2.42 (-6.91 to 2.08) |
FEV1 and ppFEV1 are defined in Outcome Measure 6.
| percent change | Cohort 4: Placebo | Cohort 4: LUM 400 mg q12h+IVA 250 mg q12h |
|---|---|---|
| Cohort 4: Relative Change From Baseline in Percent Predicted FEV1 at Day 56 | -2.20 ± 1.373 | -0.69 ± 1.423 |
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for subjects with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
| units on a scale | Cohort 2: LUM 200 mg qd+IVA 250 mg q12h (HO) - Period 2 | Cohort 2: LUM 400 mg qd+IVA 250 mg q12h (HO) - Period 2 | Cohort 2: LUM 600 mg qd+IVA 250 mg q12h (HO) - Period 2 | Cohort 2: LUM 600 mg qd+IVA 250 mg q12h (HE) - Period 2 | Cohort 3: LUM 400 mg q12h+IVA 250 mg q12h (HO) - Period 2 | Cohort 2 and 3: Placebo (HO and HE) - Period 2 |
|---|---|---|---|---|---|---|
| Cohort 2 and 3: Absolute Change From Day 28 in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Day 56 | 3.3 (-3.6 to 10.1) | 7.9 (0.8 to 14.9) | 8.9 (1.9 to 15.9) | 5.5 (-2.1 to 13.1) | 11.2 (1.3 to 21.1) | -8.6 (-14.9 to -2.2) |
CFQ-R respiratory domain is defined in Outcome Measure 17.
| units on a scale | Cohort 4: Placebo | Cohort 4: LUM 400 mg q12h+IVA 250 mg q12h |
|---|---|---|
| Cohort 4: Absolute Change From Baseline in CFQ-R Respiratory Domain Score at Day 56 | -0.82 ± 1.802 | 5.66 ± 1.864 |
BMI was defined as weight in kilogram (kg) divided by height\*height in square meter (m\^2).
| kg/m^2 | Cohort 4: Placebo | Cohort 4: LUM 400 mg q12h+IVA 250 mg q12h |
|---|---|---|
| Cohort 4: Absolute Change From Baseline in Body Mass Index (BMI) at Day 56 | 0.08 ± 0.075 | -0.04 ± 0.077 |
| kg | Cohort 4: Placebo | Cohort 4: LUM 400 mg q12h+IVA 250 mg q12h |
|---|---|---|
| Cohort 4: Absolute Change From Baseline in Weight at Day 56 | 0.16 ± 0.211 | -0.11 ± 0.216 |
Collected over Cohort 1: Day 1 up to 28 days after last dose (Last dose = Day 21); Cohort 2 and 3: Day 1 up to 28 days after last dose (Last dose = Day 56); Cohort 4: Day 1 up to 28 days after last dose (Last dose = Day 56). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: LUM 200 mg qd - Period 1 | — | 0/41 (0%) | 29/41 (70.7%) |
| Cohort 1: LUM 200 mg qd+IVA 150 mg q12h - Period 2 | — | 0/20 (0%) | 14/20 (70%) |
| Cohort 1: LUM 200 mg qd+IVA 250 mg q12h - Period 2 | — | 0/20 (0%) | 12/20 (60%) |
| Cohort 1: Placebo - Period 1 | — | 0/21 (0%) | 12/21 (57.1%) |
| Cohort 1: Placebo - Period 2 | — | 0/21 (0%) | 15/21 (71.4%) |
| Cohort 2: LUM 200 mg qd - Period 1 | — | 2/23 (8.7%) | 17/23 (73.9%) |
| Cohort 2: LUM 400 mg qd - Period 1 | — | 0/21 (0%) | 18/21 (85.7%) |
| Cohort 2: LUM 600 mg qd - Period 1 | — | 3/42 (7.1%) | 37/42 (88.1%) |
| Cohort 3: LUM 400 mg q12h - Period 1 | — | 2/11 (18.2%) | 6/11 (54.5%) |
| Cohort 2 and 3: Placebo (HO and HE) - Period 1 | — | 1/27 (3.7%) | 23/27 (85.2%) |
| Cohort 2: LUM 200 mg qd+IVA 250 mg q12h (HO) - Period 2 | — | 0/21 (0%) | 12/21 (57.1%) |
| Cohort 2: LUM 400 mg qd+IVA 250 mg q12h (HO) - Period 2 | — | 1/20 (5%) | 15/20 (75%) |
| Cohort 2: LUM 600 mg qd+IVA 250 mg q12h (HO&HE) - Period 2 | — | 4/38 (10.5%) | 26/38 (68.4%) |
| Cohort 3: LUM 400 mg q12h+IVA 250 mg q12h (HO) - Period 2 | — | 1/11 (9.1%) | 10/11 (90.9%) |
| Cohort 2 and 3: Placebo (HO and HE) - Period 2 | — | 4/27 (14.8%) | 20/27 (74.1%) |
| Cohort 4: Placebo | — | 5/63 (7.9%) | 53/63 (84.1%) |
| Cohort 4: LUM 400 mg q12h+IVA 250 mg q12h | — | 9/62 (14.5%) | 51/62 (82.3%) |
| Event | Cohort 1: LUM 200 mg qd - Period 1 | Cohort 1: LUM 200 mg qd+IVA 150 mg q12h - Period 2 | Cohort 1: LUM 200 mg qd+IVA 250 mg q12h - Period 2 | Cohort 1: Placebo - Period 1 | Cohort 1: Placebo - Period 2 | Cohort 2: LUM 200 mg qd - Period 1 | Cohort 2: LUM 400 mg qd - Period 1 | Cohort 2: LUM 600 mg qd - Period 1 | Cohort 3: LUM 400 mg q12h - Period 1 | Cohort 2 and 3: Placebo (HO and HE) - Period 1 | Cohort 2: LUM 200 mg qd+IVA 250 mg q12h (HO) - Period 2 | Cohort 2: LUM 400 mg qd+IVA 250 mg q12h (HO) - Period 2 | Cohort 2: LUM 600 mg qd+IVA 250 mg q12h (HO&HE) - Period 2 | Cohort 3: LUM 400 mg q12h+IVA 250 mg q12h (HO) - Period 2 | Cohort 2 and 3: Placebo (HO and HE) - Period 2 | Cohort 4: Placebo | Cohort 4: LUM 400 mg q12h+IVA 250 mg q12h |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CYSTIC FIBROSIS LUNGCongenital, familial and genetic disorders | 0/41 | 0/20 | 0/20 | 0/21 | 0/21 | 1/23 | 0/21 | 1/42 | 1/11 | 1/27 | 0/21 | 1/20 | 3/38 | 1/11 | 4/27 | 0/63 | 0/62 |
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 0/41 | 0/20 | 0/20 | 0/21 | 0/21 | 0/23 | 0/21 | 0/42 | 0/11 | 0/27 | 0/21 | 0/20 | 0/38 | 0/11 | 0/27 | 3/63 | 7/62 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 0/41 | 0/20 | 0/20 | 0/21 | 0/21 | 0/23 | 0/21 | 1/42 | 0/11 | 0/27 | 0/21 | 0/20 | 0/38 | 1/11 | 0/27 | 0/63 | 0/62 |
| RESPIRATION ABNORMALRespiratory, thoracic and mediastinal disorders | 0/41 | 0/20 | 0/20 | 0/21 | 0/21 | 0/23 | 0/21 | 0/42 | 1/11 | 0/27 | 0/21 | 0/20 | 0/38 | 0/11 | 0/27 | 0/63 | 0/62 |
| HYPERSENSITIVITYImmune system disorders | 0/41 | 0/20 | 0/20 | 0/21 | 0/21 | 1/23 | 0/21 | 0/42 | 0/11 | 0/27 | 0/21 | 0/20 | 0/38 | 0/11 | 0/27 | 0/63 | 0/62 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 0/41 | 0/20 | 0/20 | 0/21 | 0/21 | 0/23 | 0/21 | 0/42 | 0/11 | 0/27 | 0/21 | 0/20 | 1/38 | 0/11 | 1/27 | 1/63 | 1/62 |
| NephrolithiasisRenal and urinary disorders | 0/41 | 0/20 | 0/20 | 0/21 | 0/21 | 0/23 | 0/21 | 0/42 | 0/11 | 0/27 | 0/21 | 0/20 | 0/38 | 0/11 | 1/27 | 1/63 | 0/62 |
| BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations | 0/41 | 0/20 | 0/20 | 0/21 | 0/21 | 0/23 | 0/21 | 0/42 | 0/11 | 0/27 | 0/21 | 0/20 | 1/38 | 0/11 | 0/27 | 0/63 | 0/62 |
| PNEUMONIAInfections and infestations | 0/41 | 0/20 | 0/20 | 0/21 | 0/21 | 0/23 | 0/21 | 1/42 | 0/11 | 0/27 | 0/21 | 0/20 | 0/38 | 0/11 | 0/27 | 0/63 | 0/62 |
| Spirometry abnormalInvestigations | 0/41 | 0/20 | 0/20 | 0/21 | 0/21 | 0/23 | 0/21 | 0/42 | 0/11 | 0/27 | 0/21 | 0/20 | 0/38 | 0/11 | 0/27 | 0/63 | 1/62 |
| Event | Cohort 1: LUM 200 mg qd - Period 1 | Cohort 1: LUM 200 mg qd+IVA 150 mg q12h - Period 2 | Cohort 1: LUM 200 mg qd+IVA 250 mg q12h - Period 2 | Cohort 1: Placebo - Period 1 | Cohort 1: Placebo - Period 2 | Cohort 2: LUM 200 mg qd - Period 1 | Cohort 2: LUM 400 mg qd - Period 1 | Cohort 2: LUM 600 mg qd - Period 1 | Cohort 3: LUM 400 mg q12h - Period 1 | Cohort 2 and 3: Placebo (HO and HE) - Period 1 | Cohort 2: LUM 200 mg qd+IVA 250 mg q12h (HO) - Period 2 | Cohort 2: LUM 400 mg qd+IVA 250 mg q12h (HO) - Period 2 | Cohort 2: LUM 600 mg qd+IVA 250 mg q12h (HO&HE) - Period 2 | Cohort 3: LUM 400 mg q12h+IVA 250 mg q12h (HO) - Period 2 | Cohort 2 and 3: Placebo (HO and HE) - Period 2 | Cohort 4: Placebo | Cohort 4: LUM 400 mg q12h+IVA 250 mg q12h |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COUGHRespiratory, thoracic and mediastinal disorders | 6/41 | 4/20 | 1/20 | 1/21 | 4/21 | 3/23 | 8/21 | 12/42 | 1/11 | 6/27 | 3/21 | 5/20 | 5/38 | 3/11 | 6/27 | 12/63 | 13/62 |
| RESPIRATION ABNORMALRespiratory, thoracic and mediastinal disorders | 1/41 | 0/20 | 1/20 | 1/21 | 1/21 | 0/23 | 2/21 | 7/42 | 2/11 | 0/27 | 1/21 | 0/20 | 2/38 | 0/11 | 0/27 | 9/63 | 17/62 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 3/41 | 0/20 | 0/20 | 1/21 | 0/21 | 0/23 | 1/21 | 10/42 | 0/11 | 0/27 | 0/21 | 0/20 | 1/38 | 0/11 | 0/27 | 4/63 | 9/62 |
| HEADACHENervous system disorders | 4/41 | 0/20 | 1/20 | 4/21 | 5/21 | 1/23 | 4/21 | 4/42 | 1/11 | 5/27 | 0/21 | 2/20 | 7/38 | 2/11 | 5/27 | 11/63 | 3/62 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 0/41 | 2/20 | 0/20 | 0/21 | 0/21 | 5/23 | 1/21 | 2/42 | 0/11 | 0/27 | 3/21 | 2/20 | 3/38 | 1/11 | 4/27 | 3/63 | 3/62 |
| OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders | 2/41 | 1/20 | 2/20 | 0/21 | 2/21 | 2/23 | 0/21 | 1/42 | 1/11 | 1/27 | 1/21 | 4/20 | 0/38 | 2/11 | 1/27 | 5/63 | 3/62 |
| SPUTUM INCREASEDRespiratory, thoracic and mediastinal disorders | 0/41 | 0/20 | 0/20 | 0/21 | 0/21 | 0/23 | 0/21 | 0/42 | 0/11 | 0/27 | 0/21 | 0/20 | 0/38 | 0/11 | 0/27 | 12/63 | 10/62 |
| NAUSEAGastrointestinal disorders | 2/41 | 0/20 | 1/20 | 0/21 | 0/21 | 0/23 | 1/21 | 8/42 | 1/11 | 3/27 | 0/21 | 1/20 | 3/38 | 0/11 | 2/27 | 7/63 | 7/62 |
| PRODUCTIVE COUGHRespiratory, thoracic and mediastinal disorders | 3/41 | 1/20 | 0/20 | 2/21 | 3/21 | 2/23 | 2/21 | 6/42 | 2/11 | 5/27 | 2/21 | 1/20 | 1/38 | 2/11 | 1/27 | 3/63 | 3/62 |
| SINUS CONGESTIONRespiratory, thoracic and mediastinal disorders | 0/41 | 0/20 | 0/20 | 0/21 | 1/21 | 1/23 | 0/21 | 3/42 | 0/11 | 2/27 | 0/21 | 1/20 | 0/38 | 2/11 | 2/27 | 4/63 | 0/62 |
Full Analysis Set (FAS) for Cohort 1, 2, and 3 included all randomized participants who received at least 1 dose of study drug and FAS for Cohort 4 included all randomized participants who received any amount of study drug.
| Age, Categorical(Participants) | Cohort 1: Placebo | Cohort 1: LUM 200 mg qd/LUM 200 mg qd+IVA 150 mg q12h | Cohort 1: LUM 200 mg qd/LUM 200 mg qd+IVA 250 mg q12h | Cohort 2 and 3: Placebo (HO and HE) | Cohort 2: LUM 200 mg qd/LUM 200 mg qd+IVA 250 mg q12h (HO) | Cohort 2: LUM 400 mg qd/LUM 400 mg qd+IVA 250 mg q12h (HO) | Cohort 2: LUM 600 mg qd/LUM 600 mg qd+IVA 250 mg q12h (HO&HE) | Cohort 3: LUM 400 mg q12h/LUM 400 mg q12h+IVA 250 mg q12h (HO) | Cohort 4: Placebo | Cohort 4: LUM 400 mg q12h+IVA 250 mg q12h | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 21 | 20 | 21 | 27 | 23 | 21 | 42 | 11 | 63 | 62 | 311 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Cohort 1: Placebo | Cohort 1: LUM 200 mg qd/LUM 200 mg qd+IVA 150 mg q12h | Cohort 1: LUM 200 mg qd/LUM 200 mg qd+IVA 250 mg q12h | Cohort 2 and 3: Placebo (HO and HE) | Cohort 2: LUM 200 mg qd/LUM 200 mg qd+IVA 250 mg q12h (HO) | Cohort 2: LUM 400 mg qd/LUM 400 mg qd+IVA 250 mg q12h (HO) | Cohort 2: LUM 600 mg qd/LUM 600 mg qd+IVA 250 mg q12h (HO&HE) | Cohort 3: LUM 400 mg q12h/LUM 400 mg q12h+IVA 250 mg q12h (HO) | Cohort 4: Placebo | Cohort 4: LUM 400 mg q12h+IVA 250 mg q12h | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 10 | 8 | 13 | 9 | 11 | 9 | 19 | 5 | 31 | 29 | 144 |
| Male | 11 | 12 | 8 | 18 | 12 | 12 | 23 | 6 | 32 | 33 | 167 |
The record gives a start of Oct 2010, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2015, 1 year 6 months after primary completion. A results delay was requested in May 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lumacaftor · Ivacaftor
Vertex Pharmaceuticals Incorporated →